109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
基于患者来源类器官的侵袭性导管型乳腺癌伴肺及肝转移个性化治疗：一例报告
Authors Zheng M, Yao L, Jing N, Wang Y, Wang X, Yang J
Received 13 May 2025
Accepted for publication 3 October 2025
Published 25 October 2025 Volume 2025:18 Pages 1189—1194
DOI https://doi.org/10.2147/OTT.S540143
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Yong Teng
Miaoli Zheng,1,* Liang Yao,2,* Na Jing,1 Yu Wang,1 Xianling Wang,1 Jun Yang2
1Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, People’s Republic of China; 2Department of Breast Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jun Yang, Department of Breast Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No. 3 Zhigongxincun, Xinghualing District, Taiyuan, 030013, People’s Republic of China, Email Sc2006120@163.com Xianling Wang, Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No. 3 Zhigongxincun, Xinghualing District, Taiyuan, 030013, People’s Republic of China, Email wxl690329@hotmail.com
Abstract: Patient-derived organoids (PDOs) are emerging as a potential preclinical tool in assessing cancer patients’ responses to various therapies. Here, we first described a case of invasive ductal breast carcinoma with lung and liver metastases who obtained efficient response to the sensitive drugs identified by PDOs. A 54-year-old woman came to hospital with the chief complaint of an unpainful mass in the right breast. In combination with relevant examinations, she was diagnosed with cT3N1M0 breast cancer with HER2 amplification, but developed lung and liver metastases after use of multiple therapies. After treatment with erebulin, carboplatin and inetetamab sensitive revealed by the organoid drug sensitivity testing, partial response in lung metastasis and stable disease in liver metastasis were achieved. This typical case suggests that for the individual patients with advanced refractory breast cancer, especially those exhausting the standard treatment options, the PDOs may serve as an effective model for assessing individual drug sensitivity to optimize treatment decisions and improve treatment response.
Keywords: invasive ductal carcinoma, liver metastasis, lung metastasis, patient-derived organoids, treatment response
1Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, People’s Republic of China; 2Department of Breast Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jun Yang, Department of Breast Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No. 3 Zhigongxincun, Xinghualing District, Taiyuan, 030013, People’s Republic of China, Email Sc2006120@163.com Xianling Wang, Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, No. 3 Zhigongxincun, Xinghualing District, Taiyuan, 030013, People’s Republic of China, Email wxl690329@hotmail.com
Abstract: Patient-derived organoids (PDOs) are emerging as a potential preclinical tool in assessing cancer patients’ responses to various therapies. Here, we first described a case of invasive ductal breast carcinoma with lung and liver metastases who obtained efficient response to the sensitive drugs identified by PDOs. A 54-year-old woman came to hospital with the chief complaint of an unpainful mass in the right breast. In combination with relevant examinations, she was diagnosed with cT3N1M0 breast cancer with HER2 amplification, but developed lung and liver metastases after use of multiple therapies. After treatment with erebulin, carboplatin and inetetamab sensitive revealed by the organoid drug sensitivity testing, partial response in lung metastasis and stable disease in liver metastasis were achieved. This typical case suggests that for the individual patients with advanced refractory breast cancer, especially those exhausting the standard treatment options, the PDOs may serve as an effective model for assessing individual drug sensitivity to optimize treatment decisions and improve treatment response.
Keywords: invasive ductal carcinoma, liver metastasis, lung metastasis, patient-derived organoids, treatment response